Ocugen Inc OCGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
-
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
-
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
-
Ocugen to Participate in Upcoming Scientific Conferences
-
Ocugen to Participate in Upcoming October Investor and Industry Conferences
-
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
-
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 339.11M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 50.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 116
- Website
- https://www.ocugen.com
Valuation
|
Metric
|
OCGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 50.88 |
Price/Cash Flow | — |
Price/Earnings
OCGN
Financial Strength
|
Metric
|
OCGN
|
|---|---|
Quick Ratio | 0.75 |
Current Ratio | 0.80 |
Interest Coverage | −8.79 |
Quick Ratio
OCGN
Profitability
|
Metric
|
OCGN
|
|---|---|
Return on Assets (Normalized) | −104.55% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −153.66% |
Return on Assets
OCGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|BXsm#Pz | LOCK|>r?%x | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>yklJmc | LOCK|GY<< | $84B | |||
| Moderna Inc
MRNA
| LOCK|G@!>nZ | LOCK|XpW | $83B | |||
| argenx SE ADR
ARGX
| LOCK|k&zd?DJ | LOCK|^Q | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$kh?t# | LOCK|h>z | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|G%HX?J | LOCK|#%!L | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|R$s&x$C? | LOCK|NxHy | $29B | |||
| Incyte Corp
INCY
| LOCK|kBGKj?V | LOCK|qt# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|v<>hW&f | LOCK|tVz | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|p#R$RRK | LOCK|?# | $14B |
United States